読み込み中
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
前日終値
$96.96
+$4.90 · +5.32%
日中の時刻はETです。市場データは遅延する場合があります。
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
日中レンジ
現在 $96.96
52週レンジ
現在 $96.96
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
49
適正価値
センチメント
66
強気
リスク
41
やや高いリスク
モメンタム
38
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
日中レンジ
現在 $96.96
52週レンジ
現在 $96.96
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（EUR） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 27.57億 EUR | 27.51億 EUR | 38.19億 EUR | 173.11億 EUR | 189.77億 EUR |
| 売上原価 | 6.16億 EUR | 5.41億 EUR | 6億 EUR | 29.95億 EUR | 29.12億 EUR |
| 粗利益 | 21.4億 EUR | 22.1億 EUR | 32.19億 EUR | 143.16億 EUR | 160.65億 EUR |
| 研究開発 | 20.22億 EUR | 22.54億 EUR | 17.83億 EUR | 15.37億 EUR | 9.49億 EUR |
| 販売・一般管理 | 6.98億 EUR | 5.99億 EUR | 5.58億 EUR | 5.41億 EUR | 3.27億 EUR |
| 営業費用 | 27.64億 EUR | 35.24億 EUR | 25.29億 EUR | 16.73億 EUR | 7.81億 EUR |
| 受取利息 | 2.52億 EUR | — | 3.51億 EUR | 4736.7万 EUR | 156.37万 EUR |
| 支払利息 | 1363.96万 EUR | 1316.18万 EUR | 776.1万 EUR | 1582.15万 EUR | 562.93万 EUR |
| 減価償却費と償却費 | 3.68億 EUR | 2.98億 EUR | 1.83億 EUR | 1.23億 EUR | 7520万 EUR |
| 営業利益 | −6.24億 EUR | −13.14億 EUR | 6.9億 EUR | 126.43億 EUR | 152.84億 EUR |
| 純利益 | −10.91億 EUR | −6.65億 EUR | 9.3億 EUR | 94.34億 EUR | 102.93億 EUR |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2022年6月2日 | $2.111Irregular | 2022年6月3日 | 2022年6月17日 |
配当落ち 2022年6月2日
$2.111
Irregular
2022年6月3日基準 · 支払日 2022年6月17日
この株式へのエクスポージャーを報告している上場投資信託です。
First Trust NYSE Arca Biotechnology Index FundFBT9594.97万3.32%28.91億 USD0.55%$265.4+2.00%
iShares Biotechnology ETFIBB6829.15万0.65%108.2億 USD0.44%$206.49+3.00%
Schwab Fundamental International Large Company Index ETFFNDF1497.15万0.06%253.2億 USD0.25%$53.61+0.46%
iShares Genomics Immunology and Healthcare ETFIDNA931.19万3.05%3.2億 USD0.47%$42.17+4.33%
State Street SPDR Portfolio Developed World ex-US ETFSPDW903.55万0.02%404.62億 USD0.03%$49.98+0.64%
VanEck Biotech ETFBBH732.43万1.55%4.85億 USD0.35%$240.47+2.75%
JPMorgan BetaBuilders Europe ETFBBEU708.06万0.08%88.29億 USD0.09%$75.02+0.68%
Invesco NASDAQ Next Gen 100 ETFQQQJ666.64万0.56%12億 USD0.15%$44.96+1.12%First Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab Fundamental International Large Company Index ETFFNDFiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Developed World ex-US ETFSPDWVanEck Biotech ETFBBHJPMorgan BetaBuilders Europe ETFBBEUInvesco NASDAQ Next Gen 100 ETFQQQJAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
